Rani Therapeutics Holdings (RANI) Share-based Compensation (2021 - 2026)

Rani Therapeutics Holdings' Share-based Compensation history runs 6 years deep, the most recent figure standing at $32000.0 for Q1 2026.

• On a quarterly basis, Share-based Compensation fell 99.18% year-over-year to $32000.0 in Q1 2026; TTM through Mar 2026 was $31.7 million, a 13.59% increase from a year earlier, with the FY2025 full-year figure at $11.8 million, down 35.88% from the prior year.
• Share-based Compensation slipped to $32000.0 in Q1 2026 per RANI's latest filing, from $11.8 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $21.8 million in Q3 2024 and bottomed at -$4.3 million in Q2 2023.
• The 5-year median for Share-based Compensation is $4.3 million (2023), against an average of $7.5 million.
• Across the five-year window, Share-based Compensation tumbled 207.7% in 2023 and jumped 75072.41% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $15.3 million in 2022, then increased by 23.43% to $18.8 million in 2023, then retreated by 15.14% to $16.0 million in 2024, then slipped by 26.47% to $11.8 million in 2025, then plunged by 99.73% to $32000.0 in 2026.
• Per Business Quant, the three latest RANI Share-based Compensation figures stand at $32000.0 (Q1 2026), $11.8 million (Q4 2025), and $8.4 million (Q3 2025).